PAD and LM augmented serum levels of VEGF, IL-2, and IL-10, but attenuated serum levels of IL-6 and TNF-α; the therapeutic effect of PAD-H was the most significant (p < 0.05). The gene discussed is VEGFA; the disease is peripheral arterial disease.